Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Patients are flocking to longevity clinics when standard labs come back "normal" but they still feel unwell. A growing $2.6B industry is filling that gap — but not always with evidence-based care. Experts say physicians can reclaim this space by listening more carefully, testing more strategically, and knowing when to refer.
More patients are bypassing traditional healthcare for "longevity clinics" after being told their labs are normal — yet still feeling unwell. The global longevity clinic market is valued at $2.6 billion in 2026 and is projected to hit $6.9 billion over the next decade, driven by demand for proactive, personalized care that standard appointments often can't deliver.
Experts argue that conventional testing has real blind spots. Cardiometabolic disease, for instance, can quietly progress across fragmented lab results sitting in different systems — only visible when panels are read side by side over time. Some clinicians advocate for broader biomarker panels, more frequent monitoring, and imaging to catch what blood tests miss, like soft arterial plaque or early bone loss.
But the longevity space isn't without risk. Some clinics offer costly, low-evidence interventions — IV drips, peptides, and indiscriminate testing — that can exploit patients' trust. Physicians are urged to engage patients' wellness questions directly rather than dismissing them, anchor recommendations in evidence-based prevention, and use a clear framework for when to refer.
Key Takeaways:
Why it matters: As the longevity boom accelerates, primary care physicians face a pivotal choice — cede ground to wellness marketers or adapt their practice to meet patients where they are, with both rigor and empathy.
